Pharmaceutical Product Liability Insurance
Pharmaceutical product liability insurance is a compulsory cover under German law that protects manufacturers against strict liability for bodily injury caused by marketed drugs.
Comparison profile
- Trigger
- Occurrence
- Insured interest
- The manufacturer's strict, no-fault liability for bodily injury (death or personal injury) caused by the use of a marketed, authorisation-requiring pharmaceutical product.
- Rating basis
- Turnover from marketed authorised drugs, Therapeutic class and risk profile of the product portfolio, Territorial scope of marketing, Claims and pharmacovigilance history
- Typical limits
- Aggregate limit set with reference to the statutory strict-liability caps, typically placed through the specialised pharmaceutical reinsurance pool given the long-tail, mass-tort loss potential.
- Target segments
- Pharmaceutical manufacturers, Industry, Multinational
Insured events
- Bodily injury or death caused by a marketed drug's side effects
- Injury from manufacturing or batch defects
- Injury from inadequate warnings/labelling of an authorised drug
Key exclusions
- Drugs undergoing clinical trials in humans (covered separately under clinical trial subject/proband insurance)
- Property damage and pure financial loss
- Damage arising outside the statutory strict-liability regime's scope (e.g. non-authorisation-requiring products)
- Intentional or knowing violation of authorisation requirements
Compulsory insurance
- DE: Arzneimittelgesetz (AMG) §84 ff. and §94 require manufacturers of authorisation-requiring drugs to maintain financial security (Deckungsvorsorge) via insurance or a bank guarantee for the statutory strict liability
Concept
Pharmaceutical product liability insurance is a compulsory cover mandated under the German Medicines Act. It covers manufacturers’ strict liability for bodily injury – death or personal injury – arising from the use of marketed pharmaceutical products.
Reinsurance and Scope
This risk is reinsured through a specialized pharmaceutical reinsurance pool. The statutory strict liability regime applies only to drugs requiring marketing authorization; drugs undergoing clinical trials in humans are excluded and are instead covered through separate clinical trial subject insurance.
History
The Contergan (thalidomide) incidents, which came to light in 1961, led to a fundamental overhaul of pharmaceutical safety regulation and the introduction of statutory manufacturer strict liability, on which today’s compulsory insurance is based.
Comparison and delineation
Pharmaceutical product liability insurance is complemented by general product liability insurance: the compulsory cover responds specifically to the statutory strict liability for authorisation-requiring drugs, while ordinary product liability insurance covers fault-based claims, export markets outside the strict-liability regime, and non-bodily-injury losses (e.g. property damage) that the compulsory scheme does not reach. Manufacturers of authorised drugs therefore typically hold both covers side by side rather than treating one as a substitute for the other.